New drug targets Hard-to-Treat cancers with FGFR3 gene changes
NCT ID NCT05544552
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Cleveland Clinic - Main Campus
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute (DCI) - Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Gustave Roussy (Institut de Cancerologie Gustave-Roussy)
Villejuif, 94805, France
-
Institut Claudius Regaud, IUCT-Oncopole
Toulouse, 31059, France
-
Institut de Cancerologie de L'Ouest (ICO)
Saint-Herblain, 44805, France
-
Linear Clinical Research Limited
Nedlands, Washington, 6009, Australia
-
Macquarie University
Macquarie Park, New South Wales, 2109, Australia
-
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York, 10021, United States
-
NEXT Barcelona - Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Madrid, 28223, Spain
-
Peter MacCallum Cancer Research Unit
Melbourne, Victoria, 3000, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Seattle Cancer Care Alliance (SCCA) - South Lake Union
Seattle, Washington, 98109, United States
-
Tasman Oncology
Southport, Queensland, 4215, Australia
-
UMass Memorial Medical Center
Worchester, Massachusetts, 01655, United States
-
Vall d'Hebron Institut d'Oncologia (VHIO)
Barcelona, 08035, Spain
-
Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.